Search
PAC-1
go.drugbank.com/drugs/DB13048InvestigationalPAC-1 has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.
Clopenthixol
go.drugbank.com/drugs/DB13841InvestigationalIt is an antagonist at D1 and D2 dopamine receptors.
S-40503
go.drugbank.com/drugs/DB13938ExperimentalS-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.
Sevuparin
go.drugbank.com/drugs/DB15007InvestigationalSevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).
Thioglycolic acid
go.drugbank.com/drugs/DB15429InvestigationalThioglycolic acid is under investigation in clinical trial NCT03238105 (Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light).
Valomaciclovir stearate
go.drugbank.com/drugs/DB15651InvestigationalValomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).
SynKIR-110
go.drugbank.com/drugs/DB17365InvestigationalSynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).
Alrizomadlin
go.drugbank.com/drugs/DB17549InvestigationalIt is being investigated in cancers.[A257281,A257286]
Synonyms: (3'r,4's,5'r)-4-((6-chloro-2-oxo-1,2-dihydro-spiro(indole-3,3'-pyrrolidin)e-4'-(3-chloro-2-fluoro -phenyl)-1'-ethyl-spiro(cyclohexane-1,2'-pyrrolidine)-5'-carbonyl)-amino)-bicyclo(2.2.2)octane-1-carboxylicMBL-HCV1
go.drugbank.com/drugs/DB17776InvestigationalMBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.
Finotonlimab
go.drugbank.com/drugs/DB18859InvestigationalFinotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).